Why is Concord Drugs falling/rising?

As of 25-Jul, Concord Drugs Ltd's stock price is currently at Rs 57.23, reflecting an increase of Rs 1.12 or 2.0%. Today's price summary indicates that the stock has experienced a trend reversal, gaining after eight consecutive days of decline. Despite opening down by 2%, it reached an intraday high of Rs 57.23, outperforming its sector by 1.83%. Over the past week, the stock has seen a decline of 5.89%, but it has generated a remarkable return of 49.08% over the past year, even as profits have decreased by 13%. The stock is trading at a discount compared to its peers, and its attractive valuation, with a return on capital employed (ROCE) of 5.3, suggests potential for recovery.
In the broader market context, while Concord Drugs has outperformed the Sensex in the long term, it has struggled in the short term, with a 1-week return of -5.89% compared to the Sensex's decline of only 0.36%. However, the stock's year-to-date performance shows a gain of 50.61%, significantly higher than the Sensex's 4.25%. The rising investor participation, with a notable increase in delivery volume, indicates growing interest, which may support the stock's recovery after recent declines. Overall, while the stock has faced short-term challenges, its long-term performance and attractive valuation may contribute to its recent upward movement.